Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure

We are at a critical inflection point for children affected by HIV. In 2024 alone, 120,000 children were newly infected, and, without timely treatment, half of HIV positive infants will not reach their second birthday. Children remain left behind—a child with HIV is 6 times more likely to die than an adult without timely diagnosis. […]

Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months […]

This Breakthrough Champion Advocacy Toolkit is targeted towards strengthening the capacity of adolescents and youth to advocate for addressing HIV treatment inequalities to end AIDS. The Toolkit serves as a training manual for the Breakthrough Partnership’s adolescent champions to develop advocacy skills and gain knowledge about HIV treatment gaps and differentiated service delivery — which […]